Abstract
In response to a recent critique of a sequential clinical trials model, a version of the model is described for which the optimal stopping rule is explicitly soluble. The paper seeks to further the dialogue between practitioners and theoretician by describing, with the use of concrete formulas and graphics, a wide variety of the model's operating characteristics. Some should be of particular interest to practitioners and others should be of interest to theoreticians.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
